Oregon lawmakers, medical workers rally in Portland to ‘save Medicaid'
This comes after Democratic lawmakers say a sets the stage for cutting Medicaid, along with Medicare and Social Security.
The 'Portland Rallies to Save Medicaid' event happened at Holladay Park in Northeast Portland around 5:30 p.m.
Kotek declares state of emergency amid floods
U.S. Democratic Congressional Representatives from Oregon Maxine Dexter, Suzanne Bonamici and Andreas Salinas were in attendance. Bonamici also spoke about the during an event in Beaverton on Tuesday.
'Forty percent of our children in Oregon are covered by Medicaid. We are talking about taking away healthcare from almost half of Oregon's children. Forty-four percent of mothers who are going to give birth are dependent on Medicaid. Can you imagine a new mother going through not only the challenges of childbirth but then the bills that we all know stack up afterwards? We cannot stand by and let this happen,' Dexter said.
Also at the Portland rally were Oregon ADL-CIO President Graham Trainor, SEIU 503 President Johnny Earl, Medicaid recipients and health workers.
The event was organized by SEIU 503, who said in a press release that the potential cuts 'would impact the 1.4 million Oregonians who rely on Medicaid for their healthcare and devastate the state budget.' In addition, organizers said the cuts could jeopardize many jobs for those who work in the healthcare field.
Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
11 minutes ago
- Yahoo
DexCom Expands Access and Innovation While Balancing Headwinds
DexCom, Inc. DXCM reported second-quarter 2025 results that highlighted robust top-line growth, continued progress in expanding access and meaningful product innovation. Revenues grew 15% year over year to $1.16 billion, with broad-based contributions from both the U.S. and international markets. Management raised full-year revenue guidance to $4.6-$4.625 billion, reflecting confidence in ongoing momentum, particularly in the type 2 non-insulin segment. At the same time, the company faces competitive pressures, regulatory uncertainties and operational hurdles, all of which affect the near-term risk-reward balance. With a leadership transition ahead, DexCom remains positioned for long-term expansion. DexCom share have gained 4% so far this year against the industry's decline of 7%. The S&P 500 Index increased 8.8% in that period. Image Source: Zacks Investment Research Short-Term Growth Drivers U.S. Expansion in Type 2 Non-Insulin Coverage: The most immediate growth catalyst is the rapid expansion of coverage for type 2 non-insulin patients. As of the second quarter, DexCom secured reimbursement with all three major U.S. PBMs, providing access to nearly 6 million covered lives. This development is already translating into strong new patient starts, reinforcing management's confidence in raising guidance. Importantly, clinicians are increasingly integrating CGM into earlier stages of care, accelerating adoption within primary care channels. Stelo Momentum and Consumer Adoption: DexCom's over-the-counter biosensor, Stelo, continues to gain traction. The app surpassed 400,000 downloads this summer, with rising adoption among wellness users and prediabetic populations. Partnerships with platforms like Oura and Amazon are broadening distribution and enhancing digital integration. While Stelo currently represents just 2-3% of revenues, it demonstrates the potential for DexCom to diversify beyond traditional diabetes management into broader metabolic health. 15-Day G7 Sensor Launch: FDA clearance for the 15-day G7 sensor marks another short-term catalyst. A potential launch in the rest of 2025 should support utilization and potentially improve gross margin dynamics as reimbursement negotiations shift toward monthly coverage models. This longer-wear sensor enhances convenience and strengthens DexCom's competitive positioning. Operational Improvements in Supply Chain: After supply constraints earlier in the year, DexCom restored inventory levels by executing record production months and leveraging expedited shipping. The company also rolled out a nationwide warranty program for pharmacy customers, bolstering service reliability. These operational stabilizations should mitigate near-term disruption risk and support smoother growth in the second half. Long-Term Growth Drivers Expanding International Coverage: International revenues grew 16% in the second quarter, led by DexCom ONE+ adoption. Coverage wins in regions such as Ontario, Canada, and France underscore growing global recognition of CGM's clinical and economic value. In markets like Japan and Germany, low penetration of basal insulin users presents a substantial long-term opportunity. Management expects further international expansion across both established and emerging markets to remain a durable growth pillar. Next-Generation G8 Platform and Multi-Analyte Sensing: Looking further, DexCom's G8 sensor platform represents the next major leap in CGM technology. Designed to be 50% smaller, with multi-analyte sensing capabilities, G8 could expand the addressable market by addressing broader metabolic monitoring needs, including ketone detection. While timelines depend on clinical and regulatory milestones, G8 is expected to reinforce DexCom's innovation leadership and strengthen competitive differentiation. Broader Clinical Applications: DexCom is also advancing evidence generation to expand CGM usage beyond diabetes. Recent clinical trials demonstrated benefits for gestational diabetes and type 2 non-insulin users, while early studies suggested positive outcomes in chronic kidney disease. As real-world evidence accumulates, these findings could pave the way for new reimbursement approvals and expanded adoption across metabolic health conditions. Software and AI Integration: DexCom continues to operate with a 'consumer technology mindset,' rolling out 17 app updates in the first half of 2025 alone. Innovations such as AI-enabled smart food logging, seamless integration with wearables like Oura, and enhanced data visualization enrich user experience and increase retention. These digital enhancements help transform CGM from a monitoring device into a comprehensive health platform, reinforcing customer loyalty and utilization. DXCM's Sales & EPS Estimates Image Source: Zacks Investment Research Challenges Margin Pressures and Inventory Costs: Despite revenue growth, gross margin contracted to 60.1% from 63.5% a year ago, largely due to higher logistics costs and expedited shipping. While management expects sequential improvement as supply-chain normalization continues, sustained investment in distribution and warranty programs may weigh on profitability in the near term. Competitive and Regulatory Uncertainty: DexCom faces intensifying competition, particularly from Abbott ABT, which is strengthening its integration with insulin pumps and advancing new sensor platforms. In addition, the CMS proposal for competitive bidding in CGM and pumps, while still preliminary, poses a medium-term risk. Medicare represents roughly 15% of DexCom's business, and any pricing compression could affect margins starting as early as 2027. Leadership Transition: CEO Kevin Sayer will step down in early 2026, handing leadership to current president Jake Leach. While Leach has been with DexCom since its inception and is well regarded, transitions of this magnitude always carry execution risk. Ensuring continuity of strategic focus, particularly across innovation and global expansion, will be critical. Conservative Guidance and Execution Risk: Although management raised revenue guidance, it remains cautious about the back half, citing the need to meet commitments despite outperformance in the first half. This conservatism reflects execution challenges around scaling new coverage wins, driving sustained utilization and balancing global expansion with profitability. Competition Update Abbott continues to assert dominant momentum, driven largely by its FreeStyle Libre portfolio. The company reported a strong 18.3 % increase in continuous glucose monitor sales in first-quarter 2025, boosting medical device revenues by 9.9 % — beating EPS forecasts for the 21st consecutive quarter. Underpinning its success, Abbott projects Libre franchise annual sales could reach $10 billion by 2028, fueling investor optimism around expanded CGM adoption. Roche RHHBY has maintained steady growth across its Diagnostics arm, achieving 6% sales growth in first quarter of 2025 on a constant-exchange-rate basis. Roche is advancing CGM technology, showcasing an AI-enabled SmartGuide system that predicts glucose trends and hypoglycemia up to two hours ahead. These innovations reinforce Roche's potential to integrate predictive analytics into diabetes care and expand its CGM footprint. Medtronic MDT is gaining traction with its Smart MDI and MiniMed 780G systems. Real-world data show that users of Medtronic's Smart MDI system achieved Time-in-Range averages of 67% to 71% when acting on insulin-alert prompts. Separately, use of the Medtronic's MiniMed 780G with SmartGuard improved HbA1C by 0.6% and increased Time-in-Range by nearly 10% versus manual insulin delivery. DexCom, Inc. Price DexCom, Inc. price | DexCom, Inc. Quote Conclusion DexCom delivered another quarter of strong double-digit growth, underpinned by expanded access, international traction and product innovation. The company's leadership in CGM technology, coupled with growing evidence supporting broader use cases, provides a compelling long-term narrative. However, margin pressures, regulatory uncertainty, competitive threats and the looming CEO transition temper near-term enthusiasm. At current levels, the stock reflects both opportunity and risk in equal measure. Investors should continue to hold the stock and wait for greater clarity on execution in type 2 non-insulin adoption, international scale-up, and margin recovery before revisiting a more bullish outlook. DexCom currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Abbott Laboratories (ABT) : Free Stock Analysis Report Roche Holding AG (RHHBY) : Free Stock Analysis Report Medtronic PLC (MDT) : Free Stock Analysis Report DexCom, Inc. (DXCM) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data
CNBC
12 minutes ago
- CNBC
States brace for less disaster relief aid as Trump administration reshapes FEMA
The Trump administration is quickly reshaping the Federal Emergency Management Agency, or FEMA, in ways that carry vast implications for state and local governments. "We're going to give out less money. We're going to give it out directly. It'll be from the president's office," President Donald Trump said at a press conference June 11. The agency is responsible for coordinating response and recovery in disasters that range from floods to wildfires to terrorist attacks. The agency reported a total budget authority of $60 billion in fiscal year 2025. Federal spending on disaster relief often draws supplemental appropriations from Congress. Critics of FEMA say the agency is slow to pay out victims and provide guidance for communities in the process of rebuilding. "We've recommended for years that they work on streamlining their recovery programs, that they better coordinate their programs so communities and survivors don't have to navigate multiple federal bureaucratic programs. And honestly, they just have not been able to do it," Chris Currie, a director at the Government Accountability Office, said in an interview with CNBC. FEMA is currently managing more than 600 open disaster declarations, some of which date back almost 20 years, according to a Government Accountability Office report published in March. The spending, according to FEMA, includes $80 million in fiscal year 2025 for recovery from Hurricanes Katrina, Rita and Wilma, which devastated huge swaths of the Gulf Coast in 2005. Cuts in federal funding for disaster relief would put the burden on state and local governments in areas affected by disasters. When Hurricane Helene hit the U.S. in late September 2024, it caused $59.6 billion in damage in North Carolina, according to the Governor's Recovery Office for Western North Carolina. As of May 2025, the federal government had provided about $3.7 billion in recovery funds — approximately 6.2% of the total cost of the damage, according to Democratic Gov. Josh Stein's office. A FEMA spokesperson said in a statement to CNBC, "FEMA's principles for emergency management assert that disasters are best managed when they're federally supported, state managed and locally executed." Much work remains nearly a year after Helene damaged many parts of western North Carolina. More than 73,000 homes were damaged, according to an April report from Rep. Chuck Edwards, R-N.C. Major roadways were also damaged, including a stretch of I-40, and the state needs additional federal funds to cover the cost of road repairs, Edwards' report said. The average income in the disaster area ranges from $35,809 to $55,607, depending on the county, Edwards' report said. "To not have FEMA means that now local governments will have to deal with disaster, and it's always bigger than the revenues of the local government," said Sarah Wells Rolland, founder and owner of the Village Potters Clay Center in Asheville, North Carolina. "For the funding to be taken away I think is a colossal disaster." Wells Rolland said her business operated in Asheville's River Arts District for 13 years before Hurricane Helene passed through town. The business was destroyed by more than 24 feet of flood waters, according to NOAA. The Village Potters Clay Center, which generated about $743,000 in annual revenues in 2023, documented almost $200,000 in equipment losses, according to Wells Rolland. The business had flood insurance through FEMA's National Flood Insurance Policy and received a payment of $165,000, according to Wells Rolland. She plans to reopen this fall in a new location on higher ground. "We're an economic driver for tourism, hospitality, restaurants, regional development, you know, so we're an essential part of our economic community," said Jeffrey Burroughs, president of the River Arts District Association. "If we can't take on another loan, how do we get the funding to help sustain us so that we can stay open?" Watch the video above to see how FEMA could evolve in the coming years.
Yahoo
25 minutes ago
- Yahoo
Judge blocks Beto O'Rourke from financially supporting Texas Democrats who left the state
Former U.S. Rep. Beto O'Rourke cannot financially support Texas Democrats who left the state to delay passage of a new congressional map, a Tarrant County judge ruled Friday evening. O'Rourke and his political group, Powered by People, were sued by Texas Attorney General Ken Paxton Friday afternoon. Paxton argued that the group was deceptively fundraising for and illegally helping support Texas Democrats as they fanned out to Illinois, Massachusetts and New York to deny the House the headcount needed to pass legislation. Tarrant County District Judge Megan Fahey granted Paxton's request for a temporary injunction, barring O'Rourke and Powered by People from fundraising for the Democrats or spending money to cover their expenses. The order came less than four hours after Paxton's office filed the petition. Fahey, a Republican, was appointed by Gov. Greg Abbott in 2019 and has twice been reelected to the bench. In her ruling, Fahey agreed with Paxton's contention that Powered by People engaged in false, misleading or deceptive fundraising practices, and by distributing funds to Texas Democrats, writing in the ruling that the group either 'directly violates or causes Texas Democratic Legislators' to violate state law and House procedures. The group cannot use political funds to pay for travel or accommodations for 'unexcused Texas legislators during any special legislative session called by the Texas Governor as consideration for a violation of such legislators' Constitutional duties.' O'Rourke filed his own lawsuit against Paxton Friday in El Paso district court. He alleged that the attorney general was engaging in a 'fishing expedition, constitutional rights be damned,' and asked the judge to block Paxton's investigation into the organization's practices. In a statement responding to the injunction, O'Rourke said Paxton was trying to 'make examples out of those who fight so that others won't.' 'Paxton is trying to shut down Powered by People, one of the largest voter registration organizations in the country, because our volunteers fight for voting rights and free elections, the kind of work that threatens the hold that Paxton, [President Donald] Trump and Abbott have on power in Texas,' O'Rourke said. Paxton responded on social media: 'Cry more, lib.' The lawsuit against O'Rourke and his group is part of a larger effort to drag Democratic lawmakers back to Texas. President Donald Trump demanded that Texas redraw its congressional map to yield five additional seats to shore up the GOP's slim majority in the U.S. House ahead of the 2026 midterms. With few tools to stop the map's passage through the Republican-dominated Legislature, Democrats called on their one failsafe, leaving the state to deny quorum, or the minimum number of members required for the chamber to function. Typically, the majority party issues arrest warrants for the absentee members — which can only be enforced within state lines — and waits until quorum is restored. But this time, Republicans have gone on the offensive, filing lawsuits to cut off financial support; asking Illinois courts to enforce Texas' civil warrants; investigating members and donors for bribery; and, in an unprecedented move, asking the Texas Supreme Court to expel lawmakers who left. 'The Beto Bribe buyouts that were bankrolling the runaway Democrats have been officially stopped,' Paxton said in a statement. 'Today, I stopped his deceptive financial influence scheme that attempted to deceive donors and subvert our constitutional process. They told me to 'come and take it,' so I did.' Shape the future of Texas at the 15th annual , happening Nov. 13–15 in downtown Austin! We bring together Texas' most inspiring thinkers, leaders and innovators to discuss the issues that matter to you. Get tickets now and join us this November. TribFest 2025 is presented by JPMorganChase. Solve the daily Crossword
